This press release presents the non-GAAP financial measures “adjusted total operating expenses” and “adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.
A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
QUANTUM-SI INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) (unaudited)
|
|||||
June 30,
2024 |
December 31,
2023 |
||||
Assets | |||||
Current assets: | |||||
Cash and cash equivalents | $ |
59,552 |
$ |
133,860 |
|
Marketable securities |
|
158,565 |
|
123,876 |
|
Accounts receivable, net of allowance of $0 and $0, respectively |
|
598 |
|
368 |
|
Inventory |
|
4,854 |
|
3,945 |
|
Prepaid expenses and other current assets |
|
2,901 |
|
4,261 |
|
Total current assets |
|
226,470 |
|
266,310 |
|
Property and equipment, net |
|
16,211 |
|
16,275 |
|
Internally developed software, net |
|
124 |
|
532 |
|
Operating lease right-of-use assets |
|
13,248 |
|
14,438 |
|
Other assets |
|
695 |
|
695 |
|
Total assets | $ |
256,748 |
$ |
298,250 |
|
Liabilities and stockholders’ equity | |||||
Current liabilities: | |||||
Accounts payable | $ |
1,379 |
$ |
1,766 |
|
Accrued payroll and payroll-related costs |
|
2,883 |
|
4,943 |
|
Accrued contracted services |
|
1,645 |
|
1,519 |
|
Accrued expenses and other current liabilities |
|
3,446 |
|
1,815 |
|
Current portion of operating lease liabilities |
|
1,655 |
|
1,566 |
|
Total current liabilities |
|
11,008 |
|
11,609 |
|
Warrant liabilities |
|
478 |
|
1,274 |
|
Operating lease liabilities |
|
11,991 |
|
13,737 |
|
Other long-term liabilities |
|
11 |
|
11 |
|
Total liabilities |
|
23,488 |
|
26,631 |
|
Stockholders’ equity | |||||
Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 122,382,332 and 121,832,417 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively |
|
12 |
|
12 |
|
Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 19,937,500 shares issued and outstanding as of June 30, 2024 and December 31, 2023 |
|
2 |
|
2 |
|
Additional paid-in capital |
|
771,460 |
|
767,239 |
|
Accumulated other comprehensive loss |
|
(7) |
|
— |
|
Accumulated deficit |
|
(538,207) |
|
(495,634) |
|
Total stockholders’ equity |
|
233,260 |
|
271,619 |
|
Total liabilities and stockholders’ equity | $ |
256,748 |
$ |
298,250 |
|
QUANTUM-SI INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts) (unaudited) |
|||||||||||
Three months ended June 30, | Six months ended June 30, | ||||||||||
|
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
||
Revenue: | |||||||||||
Product | $ |
584 |
$ |
187 |
$ |
1,012 |
$ |
438 |
|||
Service |
|
38 |
|
18 |
|
67 |
|
21 |
|||
Total revenue |
|
622 |
|
205 |
|
1,079 |
|
459 |
|||
Cost of revenue |
|
268 |
|
127 |
|
456 |
|
257 |
|||
Gross profit |
|
354 |
|
78 |
|
623 |
|
202 |
|||
Operating expenses: | |||||||||||
Research and development |
|
14,381 |
|
15,834 |
|
26,482 |
|
34,001 |
|||
Selling, general and administrative |
|
12,424 |
|
11,136 |
|
23,952 |
|
22,314 |
|||
Total operating expenses |
|
26,805 |
|
26,970 |
|
50,434 |
|
56,315 |
|||
Loss from operations |
|
(26,451) |
|
(26,892) |
|
(49,811) |
|
(56,113) |
|||
Dividend and interest income |
|
2,887 |
|
2,483 |
|
6,461 |
|
4,702 |
|||
(Loss) gain on marketable securities, net |
|
— |
|
(1,181) |
|
— |
|
1,761 |
|||
Change in fair value of warrant liabilities |
|
477 |
|
(310) |
|
796 |
|
81 |
|||
Other (expense) income, net |
|
(12) |
|
327 |
|
(19) |
|
385 |
|||
Loss before provision for income taxes |
|
(23,099) |
|
(25,573) |
|
(42,573) |
|
(49,184) |
|||
Provision for income taxes |
|
— |
|
— |
|
— |
|
— |
|||
Net loss | $ |
(23,099) |
$ |
(25,573) |
$ |
(42,573) |
$ |
(49,184) |
|||
Net loss per common share attributable to common stockholders, basic and diluted | $ |
(0.16) |
$ |
(0.18) |
$ |
(0.30) |
$ |
(0.35) |
|||
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted |
|
141,939 |
|
141,507 |
|
141,856 |
|
140,897 |
|||
Other comprehensive gain (loss): | |||||||||||
Net unrealized gain on marketable securities, net of tax | $ |
28 |
$ |
— |
$ |
— |
$ |
— |
|||
Foreign currency translation adjustment | $ |
(2) |
$ |
— |
$ |
(7) |
$ |
— |
|||
Total other comprehensive gain (loss), net of tax |
|
26 |
|
— |
|
(7) |
|
— |
|||
Comprehensive loss | $ |
(23,073) |
$ |
(25,573) |
$ |
(42,580) |
$ |
(49,184) |
|||
QUANTUM-SI INCORPORATED RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (in thousands) (unaudited)
|
|||||||||||
Three months ended June 30, | Six months ended June 30, | ||||||||||
|
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
||
Net loss | $ |
(23,099) |
$ |
(25,573) |
$ |
(42,573) |
$ |
(49,184) |
|||
Adjustments to reconcile to EBITDA: | |||||||||||
Dividend and interest income |
|
(2,887) |
|
(2,483) |
|
(6,461) |
|
(4,702) |
|||
Depreciation and amortization |
|
1,387 |
|
1,090 |
|
2,448 |
|
1,893 |
|||
EBITDA |
|
(24,599) |
|
(26,966) |
|
(46,586) |
|
(51,993) |
|||
Adjustments to reconcile to Adjusted EBITDA: | |||||||||||
Loss (gain) on marketable securities, net |
|
— |
|
1,181 |
|
— |
|
(1,761) |
|||
Change in fair value of warrant liabilities |
|
(477) |
|
310 |
|
(796) |
|
(81) |
|||
Other expense (income), net |
|
12 |
|
(327) |
|
19 |
|
(385) |
|||
Stock-based compensation |
|
2,400 |
|
1,865 |
|
4,009 |
|
5,773 |
|||
Restructuring costs |
|
31 |
|
1,067 |
|
174 |
|
1,880 |
|||
Adjusted EBITDA | $ |
(22,633) |
$ |
(22,870) |
$ |
(43,180) |
$ |
(46,567) |
|||
Three months ended June 30, | Six months ended June 30, | ||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||
Total operating expenses | $ |
26,805 |
$ |
26,970 |
$ |
50,434 |
$ |
56,315 |
|||
Adjustments to reconcile to Adjusted total operating expenses: | |||||||||||
Stock-based compensation |
|
(2,400) |
|
(1,865) |
|
(4,009) |
|
(5,773) |
|||
Restructuring costs |
|
(31) |
|
(1,067) |
|
(174) |
|
(1,880) |
|||
Adjusted total operating expenses | $ |
24,374 |
$ |
24,038 |
$ |
46,251 |
$ |
48,662 |
|||